Syneos Health, Inc. - (SYNH): Price and Financial Metrics


Syneos Health, Inc. - (SYNH): $88.57

-1.10 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SYNH POWR Grades


  • Growth is the dimension where SYNH ranks best; there it ranks ahead of 98.8% of US stocks.
  • SYNH's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
  • SYNH's current lowest rank is in the Quality metric (where it is better than 28.93% of US stocks).

SYNH Stock Summary

  • Syneos Health Inc's market capitalization of $9,266,385,071 is ahead of 80.39% of US-listed equities.
  • With a one year PEG ratio of 1,053.93, Syneos Health Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.84% of US stocks.
  • SYNH's current price/earnings ratio is 46.81, which is higher than 78.9% of US stocks with positive earnings.
  • Stocks that are quantitatively similar to SYNH, based on their financial statements, market capitalization, and price volatility, are HCCI, RBC, NEOG, ICUI, and TDY.
  • SYNH's SEC filings can be seen here. And to visit Syneos Health Inc's official web site, go to www.syneoshealth.com.

SYNH Valuation Summary

  • In comparison to the median Healthcare stock, SYNH's price/sales ratio is 82.28% lower, now standing at 2.1.
  • SYNH's EV/EBIT ratio has moved down 13.3 over the prior 82 months.
  • Over the past 82 months, SYNH's price/sales ratio has gone up 0.9.

Below are key valuation metrics over time for SYNH.

Stock Date P/S P/B P/E EV/EBIT
SYNH 2021-01-22 1.8 2.6 41.2 45.3
SYNH 2020-12-29 1.6 2.3 36.4 41.3
SYNH 2020-05-20 1.3 2.1 32.0 32.0
SYNH 2020-02-12 1.5 2.4 78.5 34.6
SYNH 2019-12-24 1.3 2.1 70.9 32.3
SYNH 2017-09-27 1.8 8.1 32.0 26.9

SYNH Growth Metrics

  • The 4 year cash and equivalents growth rate now stands at 526.13%.
  • Its 3 year cash and equivalents growth rate is now at 101.13%.
  • Its 4 year net income to common stockholders growth rate is now at 78.43%.
Over the past 15 months, SYNH's revenue has gone down $214,648,000.

The table below shows SYNH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 4,461.167 591.188 197.937
2020-12-31 4,415.777 425.493 192.787
2020-09-30 4,488.712 471.715 191.951
2020-06-30 4,566.736 390.132 187.455
2020-03-31 4,720.164 293.18 194.836
2019-12-31 4,675.815 318.481 131.258

SYNH Price Target

For more insight on analysts targets of SYNH, see our SYNH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $80.92 Average Broker Recommendation 1.42 (Moderate Buy)

SYNH Stock Price Chart Interactive Chart >

Price chart for SYNH

SYNH Price/Volume Stats

Current price $88.57 52-week high $92.25
Prev. close $89.67 52-week low $50.26
Day low $88.44 Volume 824,600
Day high $90.33 Avg. volume 1,008,883
50-day MA $87.33 Dividend yield N/A
200-day MA $76.45 Market Cap 9.24B

Syneos Health, Inc. - (SYNH) Company Bio


Syneos Health, formerly INC Research Holdings, provide the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company was founded in 2010 and is based in Raleigh, North Carolina.

SYNH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$88.57$132.91 53%

Below please find a table outlining a discounted cash flow forecast for SYNH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Syneos Health Inc ranked in the 64th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 53.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Syneos Health Inc ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 74. Its equity weight surpasses that of only 22.49% of free cash flow generating stocks in the Healthcare sector.
  • Syneos Health Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 14.11% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%50%
1%51%
2%53%
3%54%
4%56%
5%57%

BDX, MGLN, SGRY, IQV, and MOH can be thought of as valuation peers to SYNH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


SYNH Latest News Stream


Event/Time News Detail
Loading, please wait...

SYNH Latest Social Stream


Loading social stream, please wait...

View Full SYNH Social Stream

Latest SYNH News From Around the Web

Below are the latest news stories about Syneos Health Inc that investors may wish to consider to help them evaluate SYNH as an investment opportunity.

Is Syneos Health, Inc.'s (NASDAQ:SYNH) Recent Stock Performance Influenced By Its Financials In Any Way?

Syneos Health's (NASDAQ:SYNH) stock is up by 3.9% over the past month. We wonder if and what role the company's...

Yahoo | July 21, 2021

Syneos Health Names Michael Brooks Chief Development Officer

Newly Created Role Demonstrates Company’s Commitment to Growth and Innovation as Industry Leader in Biopharmaceutical Product DevelopmentMORRISVILLE, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Brooks to the newly created role of Chief Development Officer. In this role, Brooks will help drive Syneos Health’s growth strategy, building a broader, proactive go-to-

Yahoo | July 14, 2021

Hedge Funds Are Selling Syneos Health, Inc. (SYNH)

No summary available.

Insider Monkey | July 12, 2021

Syneos Health Schedules Second Quarter 2021 Earnings Call for Monday, August 9, 2021

MORRISVILLE, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to its earnings call at 8:00 a.m. ET.

Intrado Digital Media | July 12, 2021

Latest Research Report On Clinical Trial Services Market 2021. Major Players Included Labcorp, IQVIA, Syneos Health, Parexel, PRA, etc.

Industry Growth Insights (IGI) announces the release of a new report, Clinical Trial Services Market Research Report 2021. The statistics and insights provide an in-depth look into the market and opportunities. The report provides a comprehensive analysis of key market shares, size, trends, and forecasts for the global Clinical Trial Services market. It also covers []

Tramways Monthly | July 11, 2021

Read More 'SYNH' Stories Here

SYNH Price Returns

1-mo -1.04%
3-mo 8.74%
6-mo 14.40%
1-year 41.96%
3-year 68.38%
5-year 98.94%
YTD 30.00%
2020 14.55%
2019 51.14%
2018 -9.75%
2017 -17.11%
2016 8.43%

Continue Researching SYNH

Want to see what other sources are saying about Syneos Health Inc's financials and stock price? Try the links below:

Syneos Health Inc (SYNH) Stock Price | Nasdaq
Syneos Health Inc (SYNH) Stock Quote, History and News - Yahoo Finance
Syneos Health Inc (SYNH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.8709 seconds.